Insights from Medical Experts
Register for live events, watch videos, and read the latest clinical perspectives on PNH
Join medical experts in PNH for a conversation about FABHALTA
Register for an event to:
- Understand the ongoing challenges for patients with PNH and the evolution of management
- Dive into the efficacy and safety data for FABHALTA in both C5i-experienced (eculizumab and ravulizumab) and complement inhibitor–naive adults with PNH
- Hear perspectives on patients who may be appropriate for FABHALTA
- Learn about the process for getting patients started
Hear what PNH medical experts have to say about FABHALTA
Who Is an Appropriate Patient for FABHALTA?
Discover How FABHALTA May Benefit Adult Patients With PNH
The Clinical Data Behind FABHALTA
Medical Experts Discuss the Use of FABHALTA
Your Questions About FABHALTA Answered
The medical experts featured in the above videos were compensated for their time by Novartis Pharmaceuticals Corporation.
Read the latest clinical perspectives on PNH
Discover FABHALTA, the First and Only FDA-Approved Oral Monotherapy for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Exploring the Switch to FABHALTA for Adult Patients With PNH
The medical experts featured in this newsletter were compensated for their time by Novartis Pharmaceuticals Corporation.